These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 23282553

  • 1. [Prophylaxis against Epstein Barr disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].
    Catalán P, Alba A.
    Rev Chilena Infectol; 2012 Sep; 29 Suppl 1():S29-31. PubMed ID: 23282553
    [Abstract] [Full Text] [Related]

  • 2. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P, ESCMID Study Group of Infection in Compromised Hosts.
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [Abstract] [Full Text] [Related]

  • 3. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV.
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [Abstract] [Full Text] [Related]

  • 4. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 5. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, Iafolla M, Doucette K, Preiksaitis JK.
    Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A, Hébert D, Davies HD, Humar A, Stephens D, O'Doherty B, Allen U.
    Transplantation; 2006 Mar 27; 81(6):856-61. PubMed ID: 16570008
    [Abstract] [Full Text] [Related]

  • 7. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation.
    Green M, Reyes J, Webber S, Rowe D.
    Transpl Infect Dis; 2001 Jun 27; 3(2):97-103. PubMed ID: 11395975
    [Abstract] [Full Text] [Related]

  • 8. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
    Xuan L, Jiang X, Sun J, Zhang Y, Huang F, Fan Z, Guo X, Dai M, Liu C, Yu G, Zhang X, Wu M, Huang X, Liu Q.
    Transplantation; 2013 Sep 27; 96(6):560-6. PubMed ID: 23842192
    [Abstract] [Full Text] [Related]

  • 9. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M.
    J Pediatr Gastroenterol Nutr; 2004 Feb 27; 38(2):198-203. PubMed ID: 14734884
    [Abstract] [Full Text] [Related]

  • 10. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL.
    Clin Transplant; 1995 Feb 27; 9(1):53-9. PubMed ID: 7742583
    [Abstract] [Full Text] [Related]

  • 11. [Prophylaxis against cytomegalovirus infection in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].
    Ferrés M, Nervi B, Ramírez P.
    Rev Chilena Infectol; 2012 Sep 27; 29 Suppl 1():S23-8. PubMed ID: 23282552
    [Abstract] [Full Text] [Related]

  • 12. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N, Gabdrakhmanova L, Hammer M, Rosenberger C, Oppert M, Volk HD, Reinke P.
    Transpl Infect Dis; 2005 Sep 27; 7(3-4):133-6. PubMed ID: 16390402
    [Abstract] [Full Text] [Related]

  • 13. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis PD, Griffiths P, Mackinnon S, Emery V, Chakraverty R.
    Transplantation; 2010 Sep 15; 90(5):564-70. PubMed ID: 20555307
    [Abstract] [Full Text] [Related]

  • 14. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R, Manuel O, Hirsch HH, Fernández-Ruiz M, López-Medrano F, Comoli P, Caillard S, Grossi P, Aguado JM, ESGICH PTLD Survey Study Group,, European Study Group of Infections in Compromised Hosts (ESGICH) from the European Society of Microbiology and Infectious Diseases (ESCMID).
    Clin Microbiol Infect; 2015 Jun 15; 21(6):604.e1-9. PubMed ID: 25686696
    [Abstract] [Full Text] [Related]

  • 15. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, Goulden N, Veys P, Amrolia PJ.
    Br J Haematol; 2011 Nov 15; 155(3):377-85. PubMed ID: 21910716
    [Abstract] [Full Text] [Related]

  • 16. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M.
    Haematologica; 2006 Aug 15; 91(8):1059-67. PubMed ID: 16885046
    [Abstract] [Full Text] [Related]

  • 17. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY.
    Transpl Infect Dis; 2019 Dec 15; 21(6):e13182. PubMed ID: 31556214
    [Abstract] [Full Text] [Related]

  • 18. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 19. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
    Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A, Pezzutto A, Riess H, Subklewe M.
    Transpl Immunol; 2007 Apr 15; 17(3):203-10. PubMed ID: 17331848
    [Abstract] [Full Text] [Related]

  • 20. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F.
    Pediatr Transplant; 2009 Feb 15; 13(1):54-62. PubMed ID: 18518912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.